PuraCap™ Pharmaceutical LLC, Acquires EpiCeram® Skin Barrier Emulsion

Share Article

Steroid-free treatment for mild, moderate, and severe atopic dermatitis in adults and children

EpiCeram Packaging

“Pediatricians have been especially receptive to the steroid-free profile of EpiCeram® for managing this often chronic skin condition.”

PuraCap™ Pharmaceutical LLC (http://www.PuraCap.com), an emerging, fully-integrated pharmaceutical company with expertise in product development, manufacturing and bringing affordable, world-class quality products to their customers, announces the acquisition of their first prescription brand, EpiCeram® Skin Barrier Emulsion (http://www.EpiCeram-US.com).

Launched in 2008, EpiCeram® is a steroid-free, fragrance-free, and non-greasy treatment for the relief of the burning and itching associated with various types of dermatoses, including atopic dermatitis, irritant dermatitis, and radiation dermatitis.[1] According to the American Academy of Dermatology, between 10% - 20% percent of children and 1% - 3% of adults world-wide have atopic dermatitis, with 90% of the cases presenting before the age of five years.[2]

In a clinical study, EpiCeram® was shown to effectively relieve the signs and symptoms of atopic dermatitis with comparable efficacy to a mid-potency topical steroid cream after twenty-eight days of treatment.[3] EpiCeram® aims to repair the skin’s natural barrier with a lipid-based formulation which has a 3:1:1 ratio of ceramide, cholesterol, and fatty acids, similar to that found in normal skin.[4]

“Steroids have been the mainstay treatment for atopic dermatitis, but they can have systemic effects when used long term,” commented Jeff Thomas, Chief Commercial Officer of PuraCap™ Pharmaceutical. “Pediatricians have been especially receptive to the steroid-free profile of EpiCeram® for managing this often chronic skin condition.”

“We are excited to launch our national pharmaceutical sales team with our first prescription brand under the PuraCap™ label,” commented Dahai Guo, Chief Executive Officer, PuraCap™ Pharmaceutical. “We look forward to expanding our global presence and branded portfolio with other unique products in the dermatologic and pediatric therapeutic areas.”

Please see attached EpiCeram® Skin Barrier Emulsion Patient Information sheet for full prescribing information and contraindications. For more information, visit http://www.EpiCeram-US.com.

About PuraCap™ Pharmaceutical LLC - PuraCap™ Pharmaceutical LLC is an emerging, fully-integrated pharmaceutical company with expertise in product development, manufacturing and bringing affordable, world-class quality products to their customers. The PuraCap™ corporate structure supports their three-prong approach for global growth with dedicated companies in the areas of prescription brands, PuraCap™ Pharmaceutical LLC; prescription generics, PuraCap™ Laboratories Inc.; and OTC and Private Label products, PuraVation™ Pharmaceuticals Inc. For more information on PuraCap™ Pharmaceutical LLC, visit the company's website at http://www.PuraCap.com.

Footnotes:
[1] PuraCap™ Pharmaceutical LLC, (2011). EpiCeram® prescribing information. South Plainfield, NJ: Author.
[2] American Academy of Dematology website http://www.aad.org.

[3] Sugarman, J.L., & Parish, L.C., (2009). Efficacy of a lipid-based barrier repair in moderate- to- severe pediatric atopic dermatitis. Journal of Drugs in Dermatology, 8 (12), 1106-1111.
[4] Bikowski, J. (2009). Understanding the structure, function, and strategies for the repair of the epidermal barrier. Practical Dermatology, 8 (2), 17-18.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Julia Kelly
Visit website